STOCK TITAN

Amylyx Pharmaceuticals to Present at the Goldman Sachs 44th Annual Global Healthcare Conference

Rhea-AI Impact
(Low)
Rhea-AI Sentiment
(Neutral)
Tags
conferences

CAMBRIDGE, Mass.--(BUSINESS WIRE)-- Amylyx Pharmaceuticals, Inc. (Nasdaq: AMLX) (“Amylyx” or the “Company”) today announced that Joshua Cohen and Justin Klee, Co-CEOs of Amylyx, will participate in the Goldman Sachs 44th Annual Global Healthcare Conference. The conference is being conducted in person in Dana Point, CA, and the fireside chat will take place on Tuesday, June 13, 2023, at 4:40pm PT/7:40pm ET.

A live webcast of the presentation can be accessed under “Events and Presentations” in the Investor section of the Company’s website, https://investors.amylyx.com/news-events/events, and will be available for replay for 90 days following the event.

About Amylyx Pharmaceuticals

Amylyx Pharmaceuticals, Inc. is committed to supporting and creating more moments for the neurodegenerative disease community through the discovery and development of innovative new treatments. Amylyx is headquartered in Cambridge, Massachusetts and has operations in Canada and EMEA. For more information, visit amylyx.com and follow us on LinkedIn and Twitter. For investors, please visit investors.amylyx.com.

Media

Amylyx Media Team

+1 (857) 799-7274

amylyxmediateam@amylyx.com

Investors

Lindsey Allen

Amylyx Pharmaceuticals, Inc.

+1 (857) 320-6244

Investors@amylyx.com

Source: Amylyx Pharmaceuticals, Inc.

Amylyx Pharmaceuticals, Inc.

NASDAQ:AMLX

AMLX Rankings

AMLX Latest News

AMLX Stock Data

138.05M
50.94M
14.24%
104.79%
8.86%
Medicinal and Botanical Manufacturing
Manufacturing
Link
United States of America
CAMBRIDGE

About AMLX

Amylyx Pharmaceuticals, Inc is a biopharmaceutical company headquartered in Cambridge, Massachusetts. Amylyx is best known for AMX0035, an experimental therapy for amyotrophic lateral sclerosis.